Agilent Technologies, Inc. (BVMF:A1GI34)
Brazil · Delayed Price · Currency is BRL | Market Cap | 209.95B +19.2% |
| Revenue (ttm) | 36.02B +9.1% |
| Net Income | 7.04B +21.3% |
| EPS | 24.82 +22.7% |
| Shares Out | n/a |
| PE Ratio | 29.81 |
| Forward PE | 23.09 |
| Dividend | 1.69 (0.47%) |
| Ex-Dividend Date | Jun 29, 2026 |
| Volume | 2 |
| Open | 360.54 |
| Previous Close | 356.30 |
| Day's Range | 360.54 - 361.30 |
| 52-Week Range | 274.17 - 410.72 |
| Beta | 1.26 |
| Analysts | n/a |
| Price Target | n/a |
| Earnings Date | Aug 26, 2026 |
About Agilent Technologies
Agilent Technologies, Inc. provides application focused solutions to the life sciences, diagnostics, and applied chemical markets worldwide. The company operates through three segments: Life Sciences and Diagnostics Markets, Agilent CrossLab, and Applied Markets. The Life Sciences and Diagnostics Markets segment offers liquid chromatography systems and components; and liquid chromatography mass spectrometry systems. This segment is also involved in the genomics, contract development and manufacturing organization, pathology, companion diagnosti... [Read more]
Financial Performance
In fiscal year 2025, Agilent Technologies's revenue was $6.95 billion, an increase of 6.73% compared to the previous year's $6.51 billion. Earnings were $1.30 billion, an increase of 1.09%.
Financial numbers in USD Financial StatementsNews
Agilent Research Catalyst Award Presented to Eastern Institute of Technology, Ningbo
SANTA CLARA, Calif.--(BUSINESS WIRE)--Agilent Technologies Inc. (NYSE: A) today announced that the Eastern Institute of Technology, Ningbo has received an Agilent Research Catalyst (ARC) Award on beha...
Agilent to Announce Third-Quarter Fiscal Year 2026 Financial Results on Aug. 26
SANTA CLARA, Calif.--(BUSINESS WIRE)--Agilent Technologies Inc. (NYSE: A) will release financial results for the third quarter of fiscal year 2026 after the stock market closes on Wednesday, Aug. 26. ...
Agilent receives EU approval for PD-L1 IHC 22C3 pharmDx
Agilent Technologies (A) announced it has received European Union, EU, certification for PD-L1 IHC 22C3 pharmDx, Code SK006, as a companion diagnostic indicated to aid in identifying patients with epi...
Agilent Receives EU Approval for PD-L1 IHC 22C3 pharmDx in Epithelial Ovarian, Fallopian Tube, or Primary Peritoneal Carcinoma
SANTA CLARA, Calif.--(BUSINESS WIRE)--Agilent Technologies Inc. (NYSE: A) today announced it has received European Union (EU) certification for PD-L1 IHC 22C3 pharmDx, Code SK006, as a companion diagn...
Agilent Increases Its Investment in HALO X-ray Technologies
NOTTINGHAM, England--(BUSINESS WIRE)-- #AgilentTechnologies--Multimillion dollar investment round to enable HALO to complete regulatory approval of its advanced security screening technology.
Agilent receives FDA approval for PD-L1 IHC 28-8 pharmDx assay
Agilent Technologies (A) received U.S. Food and Drug Administration approval for the PD-L1 IHC 28-8 pharmDx assay as a companion diagnostic to identify patients with esophageal squamous cell carcinoma...
Agilent Receives FDA Approval for PD-L1 IHC 28-8 pharmDx in Esophageal Squamous Cell Carcinoma (ESCC), Gastric, Gastroesophageal Junction (GEJ), and Esophageal Adenocarcinoma
SANTA CLARA, Calif.--(BUSINESS WIRE)--Agilent Technologies Inc. (NYSE: A) today announced that it has received U.S. Food and Drug Administration (FDA) approval for the PD‑L1 IHC 28‑8 pharmDx assay as ...
Agilent price target raised to $135 from $130 at Jefferies
Jefferies raised the firm’s price target on Agilent (A) to $135 from $130 and keeps a Hold rating on the shares. The firm’s updated outlook following the Biocare acquisition reflects…
Agilent introduces Altura SEC, Altura PLRP-S columns
Agilent (A) Technologies announced the latest expansion of its Altura HPLC column portfolio with the introduction of Altura size exclusion chromatography and Altura PLRP-S columns, designed to support...
Agilent Expands Altura Portfolio with Inert Size Exclusion and PLRP-S Columns for Biotherapeutic Analysis
SANTA CLARA, Calif.--(BUSINESS WIRE)--Agilent Technologies Inc. (NYSE: A) today announced the latest expansion of its Altura HPLC column portfolio with the introduction of Altura size exclusion chroma...
Agilent price target raised to $148 from $144 at Evercore ISI
Evercore ISI analyst Vijay Kumar raised the firm’s price target on Agilent (A) to $148 from $144 and keeps an Outperform rating on the shares. The firm’s Q2 preview for…
Agilent launches Agilent xCELLigence RTCA eSight AI
Agilent (A) Technologies announced the launch of Agilent xCELLigence RTCA eSight AI, a new AI-powered software module that simplifies label-free imaging analysis by reducing manual cell segmentation s...
Agilent Launches AI-Driven Analysis Module for Agilent xCELLigence RTCA eSight
SANTA CLARA, Calif.--(BUSINESS WIRE)--Agilent Technologies Inc. (NYSE: A) today announced the launch of Agilent xCELLigence RTCA eSight AI, a new AI-powered software module that simplifies label-free ...
Agilent resumed with an Outperform at Bernstein
Bernstein analyst Eve Burstein resumed coverage of Agilent (A) with an Outperform rating and $155 price target following a return from maternity leave. “Many things” are going right for the…
Agilent completes acquisition of Biocare Medical
Agilent (A) Technologies announced the completion of its previously announced acquisition of Biocare Medical, a global leader in clinical pathology, from an investor group led by Excellere Partners an...
Excellere Partners and GHO Capital complete sale of Biocare Medical to Agilent Technologies
Denver, CO and London, UK – 25 June 2026: Excellere Partners (“Excellere”), a Denver-based private equity firm specializing in partnering with entrepreneurs and management teams, and GHO Capital Partn...
Agilent Completes Acquisition of Biocare Medical
SANTA CLARA, Calif.--(BUSINESS WIRE)--Agilent Technologies Inc. (NYSE: A) today announced the successful completion of its previously announced acquisition of Biocare Medical, a global leader in clini...
UMH PROPERTIES, INC. WELCOMES THE 21ST CENTURY ROAD TO HOUSING ACT: A MAJOR BOOST FOR AFFORDABLE MANUFACTURED HOUSING
Freehold, NJ, June 24, 2026 (GLOBE NEWSWIRE) -- UMH Properties, Inc. (NYSE: UMH) (TASE: UMH), a real estate investment trust (REIT) specializing in manufactured home communities, today expressed stron...
Tradeweb Announces Date for Second Quarter 2026 Financial Results
NEW YORK--(BUSINESS WIRE)--Tradeweb Markets Inc. (Nasdaq: TW), a global leader in electronic trading across asset classes, will release financial results for the second quarter of 2026 on Thursday, Ju...
Agilent initiated with a Neutral at Piper Sandler
Piper Sandler analyst David Westenberg initiated coverage of Agilent (A) with a Neutral rating and $150 price target The firm launched coverage of the life science tools sector with a…
Agilent Technologies Transcript: Jefferies Global Healthcare Conference 2026
Strong revenue and margin growth were driven by innovation, tech refresh cycles, and robust performance in diagnostics, semiconductors, and advanced materials. AI and digital initiatives, new product launches, and strategic M&A are expected to sustain momentum, with significant growth anticipated in China and ATD by 2027.
Agilent announces collaboration with OpenAI, BCG
Agilent (A) Technologies announced a collaboration with OpenAI and Boston Consulting Group, BCG, to accelerate the deployment of artificial intelligence, AI, across the company’s products, operations,...
Agilent, OpenAI, BCG Collaborate to Accelerate Customer-Focused, AI-Driven Scientific Innovation
SANTA CLARA, Calif.--(BUSINESS WIRE)---- $A #BringGreatScienceToLife--Agilent Technologies Inc. (NYSE: A) today announced a collaboration with OpenAI and Boston Consulting Group (BCG) to accelerate th...
Agilent price target lowered to $165 from $180 at HSBC
HSBC analyst Sidharth Sahoo lowered the firm’s price target on Agilent (A) to $165 from $180 and keeps a Buy rating on the shares. The firm says market expectations on…
Agilent receives FDA approval for expanded use of PD-L1 IHC 22C3 pharmDx
The company states: “Agilent (A) Technologies announced that the FDA has approved the expanded use of PD-L1 IHC 22C3 pharmDx, Code GE006, for use on the Dako Omnis platform to…